Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical, headquartered in Osaka, Japan, have partnered to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.
Lung cancer is the most common cause of cancer-related mortality worldwide, and is responsible for more than 1.5 million deaths per year. The demand for personalized medicine continues to increase as it may provide a way to both improve patient care and better manage healthcare costs by targeting treatment to the individuals most likely to benefit from it.
The financial details of the agreement have not been disclosed.